Among the emerging medical uses for MDMA and psilocybin is their relative dimethyltryptamine (DMT). Although a Schedule I drug in the United States, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. Much of this research is occurring outside of
Click HERE to register for our upcoming FREE Q&A webinar on ketamine regulations and the future of therapeutic psychedelic medicines! In the next few years, the FDA will likely approve drug formulations containing psilocybin and MDMA. While there are still many unknowns concerning how psilocybin and MDMA-based drug therapies will be regulated, we believe that
Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Commonly found in tablet or crystal form, MDMA is a potent psychoactive drug with stimulant properties that produces experiences of empathy and sympathy. Both are currently prohibited in Australia, but will soon be available for therapeutic use. In so
Register Here Harris Bricken attorneys, Paul Coble, Griffen Thorne, and Vincent Sliwoski, will be presenting on the “Legal and Regulatory Landscape for Psychedelics” in the following CLE webinar on January 12th, 2023, hosted by The Seminar Group. “This program will provide an overview of emerging drug therapies, including psilocybin, ketamine infusion clinics, MDMA and other
Register Here Harris Bricken attorneys, Paul Coble, Griffen Thorne, and Vincent Sliwoski, will be presenting on the “Legal and Regulatory Landscape for Psychedelics” in the following CLE webinar on January 12th, 2023, hosted by The Seminar Group. “This program will provide an overview of emerging drug therapies, including psilocybin, ketamine infusion clinics, MDMA and other
Last week, we presented a psychedelics webinar entitled “How to Protect Your Psychedelics Business.” The panelists were Paul Coble from our Phoenix office), me (Griffen Thorne from our Los Angeles office), and Graham Pechenik of Calyx Law in San Francisco. In the webinar, we presented on business law and intellectual property issues that will affect
Register Here In a few short months, the State of Oregon will open up licensing applications for the first state-regulated psilocybin program. Other states – specifically Washington and Colorado – will likely follow suit in the near future. At the same time, ketamine clinics and telehealth operators have proliferated nationally, and a number of groups
Register Here In a few short months, the State of Oregon will open up licensing applications for the first state-regulated psilocybin program. Other states – specifically Washington and Colorado – will likely follow suit in the near future. At the same time, ketamine clinics and telehealth operators have proliferated nationally, and a number of groups
In 2023, Oregon will have a regulated psilocybin market. Colorado voters will have a chance to vote on something similar this fall (although Initiative 58 would not take effect until 2024). Other than that, not a single other state has any form of psychedelic regulation in the works. Last week, an attempt to simply decriminalize
A recently published letter (“Letter”) indicates that the Biden administration is preparing for the approval of psychedelic drugs and MDMA to treat mental illness and PTSD. This type of federal agency correspondence would have been unimaginable five or six years ago. Things are changing fast! There are well-known potential health benefits of MDMA and psychedelics
